Similar articles

• An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).

  National Advisory Committee on Immunization (NACI). National Advisory Committee on Immunization (NACI). Can Commun Dis Rep. 2009 Apr;35(ACS-3):1-40. Can Commun Dis Rep. 2009. PMID: 19400026 English, French. No abstract available.
• Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo(®)): profile report.

  Deeks ED. Deeks ED. Paediatr Drugs. 2012 Feb 1;14(1):63-5. doi: 10.2165/11206930-000000000-00000. Paediatr Drugs. 2012. PMID: 22149552 Review. No abstract available.
• Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. An Advisory Committee Statement (ACS).

  National Advisory Committee on Immunization (NACI). National Advisory Committee on Immunization (NACI). Can Commun Dis Rep. 2007 May 1;33(ACS-3):1-23. Can Commun Dis Rep. 2007. PMID: 17520774 English, French. No abstract available.
• Meningococcal disease control in countries of the African meningitis belt, 2013.

  [No authors listed] [No authors listed] Wkly Epidemiol Rec. 2014 May 16;89(20):206-14. Wkly Epidemiol Rec. 2014. PMID: 24864346 English, French. No abstract available.
• Serogroup B meningococcal vaccines.

  Zimmer SM, Stephens DS. Zimmer SM, et al. Curr Opin Investig Drugs. 2006 Aug;7(8):733-9. Curr Opin Investig Drugs. 2006. PMID: 16955685 Review.